Company

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound
BayerETR: BAYN

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound

Bayer AG (ETR: BAYN) reported its third‑quarter 2026 financial results, with group sales of €10.053 billion, up 4.1 % year‑on‑year (+1.9 % currency‑ and portfolio‑adjusted), as the Pharmaceuticals Division reached…

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications

Lynk Pharmaceuticals Expands Commercialization Partnership with Simcere – Exclusive Greater China Rights for Zemprocitinib Extended to Atopic Dermatitis and Dermatological Indications

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Academic conferenceClinical trial results

Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026

Academic conferenceADC / XDC

CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026

Academic conferenceClinical trial results

GenFleet’s GFS202A Becomes World’s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026

Academic conferenceADC / XDC

LaNova’s CLDN18.2 ADC LM-302 Shows 15-Month PFS in Gastric Cancer Phase II Data at ASCO 2026

Show More